RBC Capital Reiterates Outperform Rating on Legend Biotech Corp. (LEGN)

June 21, 2024 5:53 AM EDT Send to a Friend
RBC Capital analyst Leonid Timashev reiterated an Outperform rating and $86.00 price target on Legend Biotech Corp. (NASDAQ: LEGN).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login